PAX1 Methylation as a Potential Biomarker to Predict the Progression of Cervical Intraepithelial Neoplasia: A Meta-analysis of Related Studies

2017 ◽  
Vol 27 (7) ◽  
pp. 1480-1488 ◽  
Author(s):  
Ting Luan ◽  
Quan Hua ◽  
Xia Liu ◽  
Pengfei Xu ◽  
Yun Gu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cervical Intraepithelial Neoplasia ◽  
Web Of Science ◽  
Meta Analysis ◽  
Great Influence ◽  
Intraepithelial Neoplasia ◽  
Cochrane Library ◽  
Gene Methylation ◽  
Potential Biomarker ◽  
Number Of Patients

ObjectiveThe methylation of paired box gene 1 (PAX1) has a great influence on the process of cervical lesion. However, available evidence for the association between PAX1 methylation and cervical intraepithelial neoplasia (CIN) are inconsistent. Here, we systematically reviewed and analyzed PAX1 methylation in progress of CIN.MethodsTwo investigators independently searched eligible studies of PAX1 methylation and CIN that were published in PubMed, Cochrane Library, EMBASE, and Web of Science databases until November 30, 2016. We extracted clinicopathologic features of CIN and cervical cancel relevant to PAX1 methylation. Odds ratios (ORs) with their 95% confidence intervals (CIs) were used to assess the association between PAX1 methylation and progression of patients with CIN.ResultsSeven studies composed of 1055 patients with various stages of CIN and cervical cancel were eventually included. The results revealed that PAX1 methylation was associated with transition of CIN I to CIN II/III (OR, 0.09; 95% CI, 0.04–0.19) and CIN II/III to cervical cancer (OR, 0.16; 95% CI, 0.05–0.46), and similar results were produced in sensitivity analysis. Also, we found that the OR value was associated with average age and number of patients, publication year, and study location of included articles.ConclusionsPAX1 gene methylation was associated with the transition of CIN I to CIN II/III and CIN II/III to cervical cancer, so that it could be an auxiliary biomarker to estimate the risk of CIN progress. Moreover, PAX1 may help to determine appropriate reexaminations and treatment for patients with various stages of CIN.

scholarly journals Upregulation of Translationally Controlled Tumor Protein Is Associated With Cervical Cancer Progression

2021 ◽  
Vol 8 ◽  
Author(s):  
Xiaoyu Zhu ◽  
Ji Ren ◽  
Dianqin Xu ◽  
Di Cheng ◽  
Wei Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cervical Intraepithelial Neoplasia ◽  
Cell Lines ◽  
Cancer Progression ◽  
Protein Interactions ◽  
Intraepithelial Neoplasia ◽  
Cancer Tissue ◽  
Functional Protein ◽  
Translationally Controlled Tumor Protein ◽  
Potential Biomarker

Outside a few affluent countries with adequate vaccination and screening coverage, cervical cancer remains the leading cause of cancer-related deaths in women in many countries. Currently, a major problem is that a substantial proportion of patients are already at an advanced cancer stage when diagnosed. There is increasing evidence that indicates the involvement of translationally controlled tumor protein 1 (TPT1) overexpression in cancer development, but little is known about its implication in cervical cancer. We assessed the levels of TPT1 in surgical tissue and sera of patients with cervicitis, cervical intraepithelial neoplasia III, and cervical cancer, as well as in normal and cancerous cervical cell lines. Gene sets, pathways, and functional protein interactions associated with TPT1 were identified using the TCGA data cohort of cervical cancer. We found that the TPT1 expression was significantly increased in cervical cancer tissue compared to all nonmalignant cervical tissues, including samples of cervicitis, cervical intraepithelial neoplasia III, and normal controls. Serum level of TPT1 was also increased in cervical cancer patients compared to healthy subjects. Furthermore, elevated TPT1 expression was significantly correlated with lymph node metastasis and a low differentiation degree of the cancer. In the cancerous tissues and cell lines, selective markers of PI3K/AKT/mTOR pathway over-activation, apoptosis repression, and EMT were detected, and their interaction with TPT1 was supported by biometrics analyses. Our results, for the first time, demonstrate a strong correlation of upregulated TPT1 expression with cervical cancer progression, suggesting that TPT1 might provide a potential biomarker for cervical cancer progression.

scholarly journals Cardiac Arrhythmias in Patients with COVID-19: A Systematic review and Meta-analysis

2020 ◽  
Author(s):  
Omar Hamam ◽  
Ahmed Goda ◽  
Moustafa Eldalal ◽  
Amr Ussama ◽  
Mostafa Fahmy ◽  
...  
Keyword(s):  
Systematic Review ◽  
Confidence Interval ◽  
Cardiac Arrhythmia ◽  
Cardiac Arrhythmias ◽  
Early Identification ◽  
Web Of Science ◽  
Meta Analysis ◽  
Great Influence ◽  
Cochrane Library ◽  
Significant Heterogeneity

Background: Cardiac arrhythmia cannot be overlooked in patients with coronavirus disease 2019 (COVID-19) as it carries a great influence on the outcomes. Hence, this study aimed to build concrete evidence regarding the incidence of cardiac arrhythmia in patients with COVID-19. Methods: We performed a systematic search for trusted databases/search engines including PubMed, Scopus, Cochrane library and web of science. After screening, the relevant data were extracted and the incidences from the different included studies were pooled for meta-analysis. Results: Nine studies were finally included in our study consisting of 1445 patients. The results of meta-analysis showed that the incidence of arrhythmia in patients with COVID-19 was 19.7% with 95% confidence interval (CI) ranging from 11.7 to 27.6%. There was also a significant heterogeneity (I2 = 94.67%). Conclusion: Cardiac arrhythmias were highly frequent in patients with COVID-19 and observed in 19.7% of them. Appropriate monitoring by electrocardiogram with accurate and early identification of arrhythmias is important for better management and outcomes.

scholarly journals Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Ana Cristina L. Macedo ◽  
João Carlos N. Gonçalves ◽  
Daniela Vicente Bavaresco ◽  
Antonio José Grande ◽  
Napoleão Chiaramonte Silva ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Meta Analysis ◽  
Grey Literature ◽  
Intraepithelial Neoplasia ◽  
Hpv Infection ◽  
Superior Performance ◽  
Cochrane Library ◽  
Synthesis Methods ◽  
Eligibility Criteria

Objective. This systematic review evaluates the accuracy of the mRNA HPV biomarker in cervical smears to identify cervical intraepithelial neoplasia (CIN) 2 or 3 and cervical cancer. Data Source. Eligible studies were identified by performing a search of electronic databases on Medline via Pubmed, Lilacs, Cochrane Library, Embase, and Grey literature for papers published between January 1990 and June 2018. Study Eligibility Criteria. As no randomized studies were identified, this review focuses on observational studies in which the mRNA HPV diagnostic test was compared to a histopathology reference standard. We analyzed studies that included women screened for cervical cancer using mRNA HPV. Study Appraisal and Synthesis Methods. After screening, 61 studies including 29,674 patients met the inclusion criteria and were analyzed. Dichotomization was performed by defining CIN2 or worse (CIN2+) versus CIN1, HPV infection, and normal (CIN 1-). The analysis was discriminated by the following tests: Aptima, PreTect HPV Profeer, NucliSens EasyQ HPV, OncoTect, and Quantivirus. Results. Analyzing by technique, Aptima, with 28 studies, exhibited superior performance, showing for the outcomes CIN2+ and CIN3+ an AUC of 0.88 (0.82-0.95) and 0.91 (0.84-0.99), a pooled sensitivity of 92.8% (95%CI 91.9-93.7) and 95.6% (95%CI 94.5-96.5), and a pooled specificity of 60.5% (95%CI 59.8-61.3) and 61.9% (95%CI 61.1-62.7), respectively. Conclusion. This study supports the current hypothesis that the mRNA HPV assay is an adequate tool for secondary cervical cancer screening.

scholarly journals Octamer binding transcription factor-4 expression is associated with cervical cancer malignancy and histological differentiation: a systematic review and meta-analysis

2019 ◽  
Vol 39 (5) ◽  
Author(s):  
Zi-ye Gao ◽  
Xiao-bo Liu ◽  
Feng-mei Yang ◽  
Ling Liu ◽  
Jin-zhang Zhao ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Transcription Factor ◽  
Meta Analysis ◽  
Intraepithelial Neoplasia ◽  
Cochrane Library ◽  
Case Control Studies ◽  
Histological Differentiation ◽  
Knowledge Infrastructure ◽  
Octamer Binding Transcription Factor ◽  
Transcription Factor 4

Abstract Objective: In this work, the relationship between octamer binding transcription factor 4 (OCT-4) expression and the clinicopathological features of cervical cancer (CC) is evaluated in detail. Methods: The library databases Pubmed, Embase, Cochrane library, Wan Fang and Chinese National Knowledge Infrastructure (CNKI) were searched for research related to these concepts published from the time the databases were established until May 2018. The obtained studies are screened, extracted, and evaluated according to the inclusion and exclusion criteria, and meta-analysis is carried out via RevMan 5.3. Results: Ten case–control studies, including 408 cases of CC, 164 cases of cervical intraepithelial neoplasia (CIN), and 148 cases of normal cervix, are included in the analysis. Results show that OCT-4 levels are statistically significantly different between the CC and normal cervical tissue groups (odds ratio (OR) = 15.59, 95% confidence interval (CI): 8.70, 27.94), the CC and CIN groups (OR = 5.64, 95% CI: 3.23, 9.86), the CIN and normal cervical tissues groups (OR = 7.13, 95% CI: 2.41, 21.05), and the CC well/moderately differentiated and poorly differentiated groups (OR = 0.44, 95% CI: 0.24, 0.81). OCT-4 is not statistically significantly different between CIN I + II and CIN III tissues (OR = 0.40, 95% CI: −0.02, 0.81), the CC lymphatic and non-lymphatic metastasis groups (OR = 1.93, 95% CI: 0.83, 4.47), the FIGO I and FIGO II groups (OR = 0.79, 95% CI: 0.29, 2.13), and the adenocarcinoma and squamous cell carcinoma groups (OR = 1.55, 95% CI: 0.70, 3.44). Conclusions: The available evidence suggests that OCT-4 expression is associated with CC malignancy and histological differentiation. This finding, however, is subject to quantitative studies and quality tests.

scholarly journals Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis

2020 ◽  
Vol 302 (6) ◽  
pp. 1329-1337
Author(s):  
Junya Zhang ◽  
Keyan Cheng ◽  
Zhilian Wang
Keyword(s):  
Human Papillomavirus ◽  
Cervical Intraepithelial Neoplasia ◽  
Infection Rate ◽  
Meta Analysis ◽  
Intraepithelial Neoplasia ◽  
Hpv Infection ◽  
Screening Tests ◽  
Cochrane Library ◽  
Hpv Vaccines ◽  
Hpv Genotypes

Abstract Background and aim Data on type-specific human papillomavirus (HPV) are needed to investigate HPV-based screening tests and HPV vaccines. However, Chinese relevant data are insufficient. Therefore, this meta-analysis aimed to summarize and demonstrate the prevalence and distribution of HPV genotypes in cervical intraepithelial neoplasia (CIN) and compensate for the shortage of HPV vaccines in China. Methods The Medline, Embase, and the Cochrane Library databases, as well as references cited in the selected studies, were systematically searched for studies investigating the prevalence and distribution of HPV genotypes between January 2000 and April 2019 in China. Results A total of 8 studies were identified, which comprised 2950 patients with CIN1 and 5393 with CIN2/3. The overall HPV infection rate was 84.37%. The HPV infection rate was significantly higher in the CIN2/3 group (87.00%) than in the CIN1 group (79.56%) (χ2 = 80.095, P < 0.001). The most common HPV types in CIN1 in order of decreasing prevalence were as follows: HPV52 (20.31%), HPV16 (16.81%), HPV58 (14.44%), HPV18 (6.44%), and HPV53 (5.76%). However, in the CIN2/3 group, HPV16 (45.69%) was the predominant type, followed by HPV58 (15.50%), HPV52 (11.74%), HPV33 (9.35%), and HPV31 (4.34%). Conclusions This study suggested that HPV16, HPV52, and HPV58 were the top three types of CIN in China. The findings might provide a reference for future HPV-based cervical cancer screening tests, treatment of HPV infection, and application of HPV vaccines in China.

Sign in / Sign up

Export Citation Format

Share Document